CrownBio Resources

Read More Quick Fact SNP-NGS QC Panel for Preclinical Model and Cell Line Authentication Authenticate, characterize, and detect contamination of preclinical tumor models using our new..

Watch Now On-Demand Webinar Patient-Derived Organoid and Immune Cell Co-Cultures for Immunotherapy.. Patient-derived models are viewed as the gold standard in bridging the gap between the lab and..

Event CrownBio's Virtual AACR21 Event

April 10th - May 9th
Virtual
Register Now

Read More White Paper Utilizing Patient-Derived Tumor Organoids in Matrix HTS to Derisk Drug.. Learn how Tumor Organoids Provide a Unique In Vitro Clinical Trial Platform

Watch Now On-Demand Webinar Leveraging 3D In Vitro Models for Oncology Drug Discovery This webinar discusses the need for improved translatability using patient-derived 3D systems..

Event AACR Annual Meeting 2021

Week 1: April 10-15, 2001
Week 2: May 17-21, 2001
Virtual
www.aacr.org

Read More Quick Fact Mouse I/O RNA-Seq Panel NGS-based murine targeted panel for I/O and TME studies

Watch Now Presentation CrownBio Presentation at PBSS 2020 Patient-Derived and PDX-Derived Organoids for Oncology Drug Discovery and CAR-T Cell Development

Event Webinar: A BiTE-Sized Discussion on Next-Generation Preclinical Models

May 6, 9AM/1PM ET
Virtual
Register Now

Read More Market Reports In Vitro Models for Oncology Drug Development Compare 2D cell lines, 3D spheroids and 3D patient-derived systems such as tumor organoids, and..

Read More Quick Fact MuBase® Find the most suitable murine oncology models for your preclinical studies

Watch Now On-Demand Webinar Efficacy and irAE Assessment Of Therapeutic Antibodies With Target Specific.. The preclinical development of human-specific immunotherapeutics is currently hampered by a lack..

Read More Publication Decreasing Glioma Secondary Mutations to Delay Tumor Recurrence Temozolomide-treated glioma patients often have recurrent tumors, which are linked to secondary..

Read More Poster SITC20 Poster 738: New Breast Cancer Tumor Homograft Models Developed Establishment and Application of a Series of Genetically Engineered Mouse-Derived Breast Cancer..

Read More Poster SITC20 Poster 677: Comparing Anti-PD-1 Treatment in Germ Free vs.. Evaluation of Anti-PD-1 Efficacy in Germ-Free and Antibiotic-Treated SPF Mice Bearing MC38 Tumors

Read More Poster SITC20 Poster 647: Humanized CD137 Knock-In Mouse Model to Assess Chimeric.. Evaluation of Efficacy and Toxicity of CD137 Immunotherapy with Urelumab-mIgG1 Chimeric Antibody..

Read More Poster SITC Poster 527: Advance Immunotherapy Development with a Tumor Organoid/Immune.. Tumor Organoid and Immune Cell Co-Culture System Potentiates Immuno-Oncology Drug Development

Read More Poster SITC20 Poster 245: New hTLR8 Knock-In Mouse Model for Enhanced Immunotherapy.. Human TLR8 Knock-In Mice Potentiate Immunotherapy Responses of MC38 Syngeneic Tumors

Read More Poster SITC20 Poster 237: In Vitro Potency Assays to Assess Next Generation Checkpoint.. In Vitro Potency Assays for Immune Checkpoint Blockade using Human Primary Cells, Murine HuGEMM™..

Read More Poster SITC20 Poster 12: New In Vitro Assay to Assess Bispecific T Cell Engagers Development of an In Vitro Assay to Assess Bispecific T Cell Engagers using T Cells from CD3e..

Read More Quick Fact Tumor Organoid Immuno-Oncology Applications Harness clinically-relevant models for immunotherapy development

Watch Now On-Demand Webinar Shifting the Paradigm of Cancer Treatment: How Can Optical Imaging Help? Cancer treatment has undergone a recent paradigm shift, first towards targeted and then..

Read More Poster ENA20 Poster 207: Benchmarking Syngeneic Tumor Immunity through Immune Subset.. Syngeneic models respond differently to various checkpoint inhibitors, based on the unique..

Read More Poster ENA20 Poster 29: New Human GITR Knock-In Model for Preclinical Efficacy Studies GITR plays a vital role in T cell proliferation and antitumor activity, and GITR agonistic..

Watch Now On-Demand Webinar Next Generation Syngeneic Models to Facilitate Immuno-Oncology Research Syngeneic tumor models are critical for immuno-oncology drug discovery, but very little is known..

Read More Publication Genomic Analysis of Clinical Chinese ccRCC Samples to Guide Patient.. Large scale genomics initiatives, such as The Cancer Genome Atlas, have predominantly studied..

Read More Publication Barcode Deep NGS-Based Profiling of Oncology Samples An estimated 15-25% of cell lines used for scientific experiments are either misidentified or..

Read More Quick Fact Organoids for Oncology Drug Discovery Utilize our unique in vitro clinical trial platform

Read More White Paper When and How to Use Tumor Organoids in Drug Discovery Compare the key benefits and applications of tumor organoids alongside conventional 2D and 3D..

Watch Now Presentation CrownBio Virtual AACR 2020 Event Presentation Accelerate Cancer Drug Discovery by Utilizing a Patient-Derived Organoid Library

Read More Poster AACR20 Poster 180: Characterization and Comparison of Patient-Derived.. Patient-derived xenografts (PDX) are highly predictive in vivo models, due to their close..

Read More Poster AACR20 Poster LB-007: Genetically Engineered Organoid Models for Drug.. Organoids are a powerful translational tool for preclinical research with several advantages..

Read More Poster AACR20 Poster 2768: New Bioluminescent Orthotopic KPC Murine Homograft Model.. Advanced preclinical models are needed for drug development in pancreatic ductal adenocarcinoma..

Read More Poster AACR20 Poster 2788: Orthotopic, Bioluminescent Syngeneic Models for I/O.. Clinically relevant preclinical models recapitulating the human tumor microenvironment (TME) are..

Read More Poster AACR20 Poster 2798: Profiling the Cancer Stem Cell Components of PDX and.. Organoids are innovative in vitro 3D models, derived from stem cells from patient tissue.

Read More Poster AACR20 Poster 3328: New Online Baseline Covariate Balancing Tool Developed Effective randomization is essential for controlled, preclinical studies.

Read More Poster AACR20 Poster 4575: Universal mRNA Vaccine Proof of Concept using Syngeneic and.. Therapeutic cancer vaccines present a potential attractive immunotherapeutic approach as a..

Read More Poster AACR20 Poster 5614: Combination Anti-TIGIT and PD-1 Assessment with Double.. Combination immunotherapy has the potential to improve patient response rate to anti-PD-1..

Read More Poster AACR20 Poster 5615: Assess Human Specific Anti-CD47 Antibodies with.. Blockade of CD47/SIRPα signaling with anti-CD47 antibodies offers a promising anticancer..

Read More Poster AACR20 Poster 5616: Evaluate Immunotherapy Mechanism of Action with Immune Cell.. Cancer immunotherapies often work through more than one mechanism of action, mediated by..

Read More Poster AACR20 Poster 5963: Characterizing Preclinical Murine I/O Model Tumor-Immune.. Cancer is a heterogeneous disease, which is highly related to the immune system.

Read More Quick Fact Genomics Services Advanced genomic analysis of preclinical study samples

Watch Now On-Demand Webinar In Silico Applications for In Vitro Drug Discovery To fully understand vast in vitro datasets and maximize translatability, analysis by qualified..

Read More White Paper 3 Preclinical Strategies to Identify Predictive Cancer Biomarkers Explore the Benefits of Biomarker Discovery in Early-Stage Drug Development

Watch Now On-Demand Webinar Tumor Organoids: A Paradigm Shift in Oncology Drug Discovery More clinically relevant models are urgently needed for preclinical oncology drug development.

Watch Now On-Demand Webinar Identifying Preclinical Immunotherapy Candidates Using a NHP Exploratory.. Learn how to leverage NHP exploratory toxicology studies to guide and explore lead optimization,..

Watch Now On-Demand Webinar 3D In Vitro Drug Discovery: When and How to Use Tumor Organoids The translatability of oncology cell lines and models used for preclinical in vitro drug..

Read More White Paper How to Detect, Characterize, and Evaluate CAR-T Cell Therapies Preclinical assessment of CAR-T cell therapies is challenging due to the lack of a single model..

Watch Now On-Demand Webinar 3 Strategies to Identify Clinically Predictive Biomarkers in the Preclinical.. Robust and sensitive biomarker discovery and validation is key to identifying the right patient..

Read More Quick Fact Rare Cell Analysis Sensitively detect, isolate, and characterize rare cells

thumb-wp-applications-of-hub-tumor

Read More White Paper Disrupting the Oncology Drug Development Workflow with PDXO Models Models with improved clinical relevance are needed for early stage preclinical drug development,..

thumb-publication-chapter12

Read More Publication Key In Vivo Model Uses Across Cancer Drug Target Research In vivo tumor models are widely used to evaluate anticancer agents in the preclinical setting,..

Read More White Paper Advanced Statistical Analyses to Optimize MCTs Mouse clinical trials (MCT) using PDX models are a predictive and powerful platform to determine..

Watch Now On-Demand Webinar Applications of HUB Tumor Organoids in Oncology Drug Discovery Tumor organoids offer an innovative and predictive in vitro platform to revolutionize oncology..

thumb-qf-bioinformatics

Read More Quick Fact Bioinformatics Integrated in silico modeling to accelerate drug discovery

thumb-aacr-nci-eortc19-a009

Read More Poster AACR-NCI-EORTC Poster A009: Imaging Systemic Hematologic Xenografts Establishment and Application of a Series of Systemic Bioluminescent Hematologic Cell Line..

thumb-aacr-nci-eortc19-a010

Read More Poster AACR-NCI-EORTC Poster A010: Enhancing Syngeneic Immunogenicity through OVA.. Development of OVA-Expressing Immunogenic Syngeneic Mouse Tumor Models: CT26-OVA and B16-OVA

thumb-aacr-nci-eortc19-a025

Read More Poster AACR-NCI-EORTC Poster A025: Correlating PDX Genomic and Proteomic Profiles Comparative Analysis of Proteomic and Transcriptomic Profiles of a Panel of Gastric Carcinoma..

thumb-aacr-nci-eortc19-a026

Read More Poster AACR-NCI-EORTC Poster A026: Developing an Automated Biomarker Discovery Platform An Automated Biomarker Discovery Platform based on In Vitro Pharmacology Raw Data

thumb-aacr-nci-eortc19-b041

Read More Poster AACR-NCI-EORTC Poster B041: Imaging Orthotopic Syngeneic Models Establishment of Orthotopic Syngeneic Models using Bioluminescent Imaging to Recapitulate the..

thumb-aacr-nci-eortc19-b068

Read More Poster AACR-NCI-EORTC Poster B068: New PDX-Derived Organoid (PDXO) Platform Establishing a Large Tumor Organoid Biobank using a Well-Characterized/Annotated Patient-Derived..

thumb-aacr-nci-eortc19-b142

Read More Poster AACR-NCI-EORTC Poster B142: New Immuno-Oncology Organoid Assay Co-Culture of Tumor Organoids with Immune Cells for Immuno-Oncology Drug Development

thumb-aacr-nci-eortc19-c102

Read More Poster AACR-NCI-EORTC Poster C102: Understanding Anti-PD-1 MOA Through Immune Cell.. Investigating Mechanisms of Action (MOA) of Anti-PD-1 Treatment by Systematic Depletion of..

thumb-aacr-nci-eortc19-c118

Read More Poster AACR-NCI-EORTC Poster C118: Implantation Site Effects on PDX Transcriptome Comparison of Orthotopic and Subcutaneous Patient-Derived Xenografts

thumb-qf-biomarker-discovery

Read More Quick Fact Biomarker Discovery Increase your success rate by bridging discovery knowledge to clinical results

thumb-qf-proxy-study

Read More Quick Fact Proxy Study Director System Simplify global contract research with a local point of contact

thumb-odw-cart-cell-therapies

Watch Now On-Demand Webinar How to Detect, Characterize, and Evaluate CAR-T Cell Therapies CAR-T cell therapy is a rapidly advancing I/O treatment approach, genetically modifying a..

thumb-qf-cytokine-chemokine

Read More Quick Fact Cytokine and Chemokine Profiling Rapidly quantify bioactive proteins via high throughout profiling

thumb-qf-histology-digital-pathology

Read More Quick Fact Histology and Digital Pathology Accurately visualize drug effect through next generation IHC and IF

thumb-publication-car-t-cell-gastric-cancer

Read More Publication Assessing CAR-T Cell Therapy for Gastric Cancer with PDX Models Despite advances in gastric cancer treatment and surgical techniques, overall survival rates for..

thumb-qf-biomarker-services

Read More Quick Fact Biomarker Services Proteomic and genomic assays to uncover biomarkers of response

thumb-wp-hub-organoid-technology

Read More White Paper Advantages in 3D In Vitro Modeling with HUB Organoids Organoids, or “mini organs” in a dish, have recently been developed after many decades of..

thumb-odw-hub-organoids

Watch Now On-Demand Webinar Demonstrating Clinical Relevance in 3D In Vitro Modeling with HUB Organoids Organoid technology has enormous potential for oncology research and anticancer agent drug..

thumb-toxicity-using-nhps

Read More White Paper Identifying Immune-Related Toxicity with Non-GLP Exploratory NHP Toxicology.. The safety of immunotherapies is a major clinical concern which needs to be addressed early in..

thumb-type1-diabetes

Read More Quick Fact Type 1 Diabetes Models Progress your antidiabetic agents with spontaneous and accelerated T1D models

thumb-peritonitis-models

Read More Quick Fact Peritonitis Models Increase your study confidence using validated in vivo models

thumb-bmc-cancer

Read More Publication How to Design, Apply, and Use Mouse Clinical Trials Mouse clinical trials (MCTs) employ panels of preclinical models in population-based efficacy..

resources-video-thumb-nhps

Watch Now On-Demand Webinar Assessing Immunotherapy Toxicity in NHPs Understand the NHP model features that provide an ideal preclinical model for elucidating..

thumb-wp-preclinical-oncology

Read More White Paper Imaging Orthotopic and Metastatic Preclinical Tumor Models Orthotopic models provide a more predictive alternative, allowing establishment of a relevant..

thumb-wp-ibd-models

Read More White Paper Choosing and Implementing the Most Appropriate IBD Model There is a vast array of preclinical inflammatory bowel disease (IBD) models, each with their..

thumb-wp-pancreatic-cancer

Read More White Paper Advanced Models and Novel I/O Technologies for Preclinical PDAC Research Pancreatic cancer is a challenging disease due to resistance to a range of anticancer agents and..

wp-mazimize-io-translatability

Read More White Paper Optimizing Syngeneic Translatability through POC and Target Engagement Studies While syngeneic tumor model use is widespread in preclinical immunotherapy drug development,..

thumb-nhp-exploratory-toxicology

Read More Quick Fact NHP Exploratory Toxicology De-risk the path to GLP with early toxicity screening of I/O agents

thumb-qf-inflammation-sle-models

Read More Quick Fact SLE Models Advance SLE agent development with robust in vivo models

thumb-qf-inflammation-ms-models

Read More Quick Fact MS Models In vivo models to progress your MS inflammation agents to the clinic

thumb-aacr19-5111

Read More Poster AACR Poster 5111: New Web Platform for Preclinical Data Analysis HuPharm: An interactive data analysis platform for preclinical studies

thumb-aacr19-4976

Read More Poster AACR Poster 4976: Human CD40 Agonist Antibody Assessment with Human CD40 KI.. Ex Vivo Functional Characterization and In Vivo Efficacy Validation of Human CD40 Agonistic..

thumb-aacr19-4621

Read More Poster AACR Poster 4621: Tumor Homografts for Prostate Cancer Combination Therapy.. Developing Genetically Modified Homograft Models of Mouse Prostate Cancer for Efficacy..

thumb-aacr19-4613

Read More Poster AACR Poster 4613: Evaluating Mathematical Models of Tumor Growth Kinetics Mathematical Modeling of Tumor Growth in Mouse Models

thumb-aacr19-4610

Read More Poster AACR Poster 4610: Predictive Biomarker Discovery in CRC using PDX Models Prognostic Impact of KRAS Driver Mutations and GSTT1 Expression in Colorectal Cancer to FOLFOX..

thumb-aacr19-4609

Read More Poster AACR Poster 4609: Varied Panel of Sarcoma PDX Models Developed Establishment of Sarcoma PDX Models with Various Subtypes for Drug Efficacy Evaluation

thumb-aacr19-4124

Read More Poster AACR Poster 4124: Optimizing a Functional ICB Screening Assay System Expression of Co-Inhibitory Molecules May Impact Immune Checkpoint Therapies

thumb-aacr19-3418

Read More Poster AACR Poster 3418: Authenticating Tumor Models with an NGS-Based SNP Array A NGS-Based SNP Array for the Identification of Human Xenograft Tumors, Mouse Homograft Tumors,..

thumb-aacr19-2375

Read More Poster AACR Poster 2375: Combination I/O Assessment with Double KI Checkpoint Target.. Developing Double Knock-In Models of Human Immune Checkpoint Targets (dKI HuGEMM™) for Efficacy..

thumb-aacr19-2342

Read More Poster AACR Poster 2342: Developing GvHD Models with Human PBMCs and CD34+ Cells Experimental Modeling of Acute- and Chronic-GvHD by Xenotransplanting Human Donor PBMCs or Cord..

thumb-aacr19-1925

Read More Poster AACR Poster 1925: New PDX-Derived Cancer Organoids Developed Establishment and Characterization of 3D Cancer Organoids as Clinically Relevant Ex Vivo Drug..

thumb-aacr19-1503

Read More Poster AACR Poster 1503: Immune Cell Depletion Affects aPD-1 Efficacy Effect of Immune Cell Depletion on Response to PD-1 Treatment in Syngeneic Models

thumb-aacr19-1443

Read More Poster AACR Poster 1443: New Method for Detecting and Monitoring CAR-T Cells in.. Sensitive Detection and Quantification of CAR-T Cells in Treated Patients

thumb-aacr19-1060

Read More Poster AACR Poster 1060: Prostate Cancer PDX for Predictive Preclinical Studies Establishment of a Panel of Prostate Patient-Derived Xenograft (PDX) Models and Evaluation of..

thumb-aacr19-87

Read More Poster AACR Poster 87: Bioluminescent Imaging of Orthotopic Syngeneic Models Recapitulating the Orthotopic Tumor Microenvironment using Bioluminescent Syngeneic Models in..

thumb-qf-syngeneic-models

Read More Quick Fact Syngeneic Models Well-characterized syngeneic tumor models for immunotherapy assessment

thumb-qf-muscreen

Read More Quick Fact MuScreen Syngeneic and tumor homograft in vivo immunotherapy screening

thumb-poster-muprime-tumor-homografts

Read More Quick Fact MuPrime Tumor Homografts Immunocompetent models carrying clinically-relevant oncogenic mutations

thumb-qf-hugemm-hucell-1

Read More Quick Fact HuGEMM and HuCELL Humanized drug target models for immunotherapy evaluation

thumb-qf-genectically-modified-models

Read More Quick Fact Genetically Modified Models Reliable, stable, proven technology for custom animal model generation

thumb-odw-pacreatic-cancer-research

Watch Now On-Demand Webinar How to Leverage Tumor Models for Pancreatic Cancer Research Pancreatic cancer is a challenging disease to research, in both the preclinical and clinical..

odw-imaging-thumb

Watch Now On-Demand Webinar Imaging Orthotopic and Metastatic Preclinical Models for Oncology Drug Discovery Orthotopic tumor models have many advantages over subcutaneous counterparts, including..

thumb-poster-sf19

Read More Poster Prostate Cancer Tumor Homografts for I/O Assessment New preclinical models are needed for prostate cancer drug development, which can be used to..

thumb-odw-exploring-translational-capabilities

Watch Now On-Demand Webinar Exploring Translational Capabilities of Preclinical IBD Models The development of a variety of preclinical models has advanced our understanding of underlying..

thumb-odw-preclinical-prostate

Watch Now On-Demand Webinar Preclinical Prostate Cancer Models: Which One is Right For You? Preclinical prostate cancer research is hampered by a lack of predictive models to investigate..

thumb-poster-nc3r

Read More Poster Poster: Using PDX for In Vivo CAR-T Cell Therapy Assessment Efficient growth suppression of pancreatic cancer PDX by fully human anti-mesothelin CAR-T cells

thumb-ena18-poster329

Read More Poster Poster 329: Orthotopic Syngeneics: More Clinically Relevant I/O Models Recapitulating the orthotopic tumour microenvironment using bioluminescent syngeneic models in..

thumb-ena18-poster327

Read More Poster Poster 327: Prostate Cancer Patient-Derived Xenograft Treatment Data Evaluation of anti-androgen therapy in a panel of prostate patient-derived xenograft models

thumb-ena18-poster313

Read More Poster Poster 313: Orthotopic Homograft Tumours Display Distinct TIL Patterns Orthotopic homograft tumours (syngeneic) display distinct tumour infiltrate immune cell patterns..

thumb-ena18-poster312

Read More Poster Poster 312: Comparing Kidney Cancer Genomics Across Populations Genomic characterisation of Chinese clear cell renal cell carcinoma revealed novel prognostic..

thumb-ena18-poster305

Read More Poster Poster 305: Comparing Categorical Response Methods for Tumour Model Studies Evaluation of categorical response methods in predicting drug responses in transplanted tumour..

thumb-ena18-poster250

Read More Poster Poster 250: Tumour Homografts for Prostate Cancer I/O Development Establishment of mouse prostate homograft tumour models for efficacy evaluation of combinatory..

thumb-ena18-poster241

Read More Poster Poster 241: Characterising Syngeneics to Guide Model Selection Utilising murine syngeneic model systems in I/O drug discovery: broad applications and guidance..

thumb-ena18-poster240

Read More Poster Poster 240: Evaluate Bispecific Antibodies with PBMC-Humanised Models Establishment and application of a panel of PBMC-humanised mouse tumour models in..

thumb-ena18-poster226

Read More Poster Poster 226: Immune Checkpoint Double Knock-In Models for I/O Testing Generation of human immune checkpoint double knock-in mice (dKI HuGEMM™) for preclinical..

thumb-publication-car-t-cells

Read More Publication Assessing CAR-T Cell Therapy for Pancreatic Cancer with PDX Models Despite an improvement in our knowledge of pancreatic cancer biology, standard of care treatment..

Read More Publication Profiling the TME of PDAC Tumor Homografts Pancreatic ductal adenocarcinoma (PDAC) does not respond to a range of cancer therapies (e.g...

thumb-mct-publication

Read More Publication Using MCT to Identify EGFR Predictive Biomarker in ESCC Epidermal growth factor receptor (EGFR) is reportedly overexpressed in most esophageal tumors...

odw-thumb-xenografts

Watch Now On-Demand Webinar Patient-Derived Xenografts as Models for Metastatic Breast Cancer and.. Breast cancer is a highly heterogeneous, complex disease affecting millions of women worldwide...

Read More Poster Poster 3.9: Novel Uses for PDX Models in Preclinical Drug Development Cancers are diverse genetic and immunological abnormalities, which results in specific..

thumb-wp-new-advancements

Read More White Paper New Advancements in Preclinical Prostate Cancer PDX Models Enhance Prostate Cancer Drug Development with More Translational Preclinical Models including..

thumb-tumor-models-17

Watch Now Presentation Tumour Models London 17 Presentation - Dr Rajendra Kumari There is an increasing demand for clinically relevant and predictive models in preclinical..

Read More Quick Fact DMPK Services Determine the in vivo PK profile of your new agents

thumb-wp-immunocompetent-murine-models

Read More White Paper Immunocompetent Murine Models: A Guide to Understanding their Place in.. The Challenge: How to Explore and Evaluate Novel Immunotherapies and Combination Regimens before..

Read More Poster Assess Targeted I/O Agents with PBMC-Humanized Models There is an increasing need for fast, reliable, and cost-effective immunocompetent models for..

poster-3d-ex-vivo

Read More Poster Discover Robust 3D Ex Vivo Compound Screening Ex vivo cancer pharmacology has shown advantages over in vitro and in vivo approaches in..

Read More Poster Novel PDAC Murine Homografts for I/O Drug Development Preclinical, immunocompetent models are needed for immunotherapy drug development in pancreatic..

human-cd3-thumb

Read More Poster Bispecific Antibody Evaluation via CD3E Transgenic Model Preclinical development and evaluation of T cell-redirecting antibodies is often blocked by a..

bioluminescent-syngeniec-models-thumb

Read More Poster Bioluminescent Orthotopic Syngeneics for I/O Assessment There are limited treatment options available for hepatocellular carcinoma (HCC), which is an..

poster-60-thumb

Read More Poster In Vitro Assay Platform to Test Anti-CD47 Agents CD47 is a transmembrane protein belonging to the immunoglobulin family. It acts as a “don’t eat..

poster-230-thumb-1

Read More Poster Improved CD3E Transgenic Mouse Model for I/O Agent Testing Preclinical models are required to test T cell-redirecting bispecific antibodies targeting CD3E...

1016-video-thumb

Read More Poster Investigating the TME through PDX RNAseq Analysis Cancers are collections of diverse diseases, of both genetic and immunological abnormalities...

Read More Poster WES and RNAseq Comparison of PDX Mutations Patient-derived xenografts (PDX) are widely used, highly predictive, preclinical oncology..

1144-video-thumb

Read More Poster KPC Homograft Models for PDAC Combination I/O Studies Pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult to treat cancer types,..

1264-video-thumb

Read More Poster Microbiota Enrichment Associated with PD-1 Response Studies have shown that the gut microbiome may influence antitumor immune response via innate..

Read More Poster DLBCL PDX Models with Diverse Genotypes for BTKi Testing Bruton's tyrosine kinase (BTK) activation is a major oncogenic driver for various B cell-derived..

3809-video-thumb

Read More Poster IDO1 Inhibition Assay Measuring Kyn Levels Developed IDO1 is a major mechanism of immunosuppression in tumors, with expression of IDO1 by tumor cells..

3861-video-thumb

Read More Poster New Ex Vivo PDX Compound Screening Platform Patient-derived xenograft (PDX) models are in high demand in preclinical drug development due to..

4059-video-thumb

Read More Poster TIL-Treg Subtype Shift Induced by Vaccination Tumor infiltrating lymphocytes, including regulatory T cells (Treg), are believed to play a..

4556-video-thumb

Read More Poster Disrupting the CD47-SIRPa Anti-Phagocytic Axis in I/O Macrophages provide an important surveillance system, which can be escaped by human tumors..

5033-video-thumb

Read More Poster Recapitulating the TME in Ex Vivo 3D Tumor Growth Assay The assessment of novel tumor microenvironment (TME) targeting therapies is currently hindered..

5116-video-thumb

Read More Poster Using Genetic Features to ID and QC Murine I/O Models Mouse tumor homografts (derived from syngeneics, GEMM, etc.) engrafted in their corresponding..

5669-video-thumb

Read More Poster CD3E Transgenic Mouse Model for Bispecific Antibody Testing T cell-redirecting therapy is taking a prominent role in immuno-oncology. Recent research has..

5677-video-thumb

Read More Poster PBMC-Humanized Models for Targeted Cancer Immunotherapy Monoclonal antibodies and checkpoint inhibitors have achieved remarkable clinical success in..

establishment-of-kras-thumb

Read More Poster KPC Homograft Models for PDAC Combination Immunotherapy Development Pancreatic ductal adenocarcinoma (PDAC) has a poor 5-year survival rate and remains one of the..

preclinical-efficacy-evaluation-thumb-1

Read More Poster Humanized OX40 Mouse Models for Preclinical I/O Studies OX40 is a co-stimulatory receptor of the TNF receptor superfamily, and is at the forefront of..

transcriptomic-analysis-thumb

Read More Poster Using PDX as Surrogate Models for TME Investigation Cancers are being increasingly recognized as collections of diverse immune diseases, on top of..

Read More Poster PBMC-Humanized Models for In Vivo I/O Studies The recent rise in cancer immunotherapy research and drug approvals is providing promising..

CrownBio-Tumor-Models-London-2017-thumb

Read More Poster Orthotopic, Bioluminescent Syngeneic HCC Models for Immunotherapy Assessment There are currently limited treatment options for hepatocellular carcinoma (HCC), which is a..

NGCS-2017-poster-ovarian-cancer-bioluminescent-imaging-thumb

Read More Poster Orthotopic, Bioluminescent Ovarian Cancer Xenograft Models Developed Due to late diagnoses and common treatment failure, ovarian cancer has a high lethality, and is..

WPC-EU-2017-thumb

Read More Poster Evaluate Human Origin OX40 Therapeutics In Vivo OX40, a member of the TNF superfamily, is now at the forefront of the field known as “T cell..

SITC-2017-poster-thumb

Read More Poster Evaluate Human-Specific Immunotherapies In Vivo Immunotherapies have demonstrated considerable success in oncology research, treating a variety..

A27-syngeneic-popn-study-thumb

Read More Poster Immunosuppressive Phenotype and Poor I/O Agent Response Correlation While checkpoint inhibitors are proving highly successful in oncology, a large proportion of..

A63-KPC-Shanghai-AACR-thumb

Read More Poster KPC Homograft Models for PDAC I/O Efficacy Studies Pancreatic ductal adenocarcinoma (PDAC) has a poor 5-year survival rate and remains one of the..

A64-MuScreen-Shanghai-AACR-thumb

Read More Poster In Vivo Syngeneic Screening Platform for Immunotherapeutics Syngeneic tumor models are the current workhorse in immunotherapy evaluation. They have a long..

A65-Microbiota-thumb

Read More Poster Anti-PD-1 Treatment Induces Gut Microbiota Changes Commensal microbiota plays an important role in both physiological and pathological processes..

B20-Survivalanalysis-Shanghai-AACR-thumb

Read More Poster Frailty Models Better Assess Drug Efficacy in MCTs Mouse clinical trials (MCTs) use a cohort of patient-derived xenograft (PDX) models to evaluate..

B21-combination-effects-AACR-Shanghai-thumb

Read More Poster Evaluate and Quantify Two-Drug Combination Effects In Vitro Combination therapy provides the opportunity for increased efficacy and reduced toxicity and..

B59-Lymphoma-Shanghai-thumb

Read More Poster Clinically Relevant DLBCL PDX Models for BTK Inhibitor Testing The activation of Bruton's tyrosine kinase (BTK) is considered as a major oncogenic driver for..

B73-OX40-Shanghai-AACR-thumb

Read More Poster Human OX40 Knock-In Model for I/O Agent In Vivo Testing OX40 is a co-stimulatory molecule and a member of the TNF superfamily, and is at the forefront..

B74-MiXeno-AACR-Shanghai-thumb

Read More Poster Characterization of PBMC Humanized Models for I/O Studies The recent growth in cancer immunotherapy has provided both promising treatment options for..

B75-phenotyping-AACR-Shanghai-thumb

Read More Poster Comprehensive Profiling of a Variety of I/O Models Immunotherapies such as checkpoint inhibitors have achieved great success in treating cancer..

video-humanized-models

Watch Now Presentation Tumor Models San Francisco 2018 Presentation - Dr H Toni Jun While immunotherapy continues to dominate cancer research, a number of questions and challenges..

B78-CD47-AACR-Shanghai-thumb

Read More Poster Disrupting the CD47-SIRPa Anti-Phagocytic Axis: A Novel I/O Approach Most human tumors express CD47 to escape macrophage surveillance. Therefore reinstating..

B80-combination-Shanghai-AACR-thumb

Read More Poster Combination Screening of I/O and Targeted Agents In Vitro To advance preclinical immuno-oncology drug discovery, CrownBio has developed a syngeneic model..

Watch Now Presentation EORTC 17 Short Talk - Dr Henry Q. Li It is being increasingly recognized that cancers are not just genetic diseases, but are also..

A003-AML-thumb2

Read More Poster Immunocompetent AML Model for Preclinical Efficacy Testing Acute myeloid leukemia (AML) treatment options stagnated for many years, until the approval of..

A009-Prostate-PDX

Read More Poster Characterization of Prostate Cancer PDX Models Prostate cancer is the second most common cancer worldwide for males, and the fourth most common..

Read More Poster Orthotopic, Bioluminescent Syngeneic HCC Models Developed Hepatocellular carcinoma (HCC) is an aggressive cancer type with limited therapeutic treatment..

A013-PDX-annotation

Read More Poster Discover the World’s Largest, Well-Characterized PDX Collection Patient-derived xenograft (PDX) models are recognized as the most predictive preclinical models,..

A026-Henry-Cetxuimab-response-carcinoma-FINAL

Read More Poster Cetuximab Response vs EGFR Expression Analysis Currently, the link between cetuximab treatment response and EGFR expression level is unclear...

Read More Poster Evaluate Human-Specific TIM-3 Immunotherapeutics In Vivo Research is currently ongoing on how to improve the low overall response rate to checkpoint..

A207-OX40-thumb

Read More Poster Evaluate the Efficacy of Human OX40 Therapeutics and Combination Regimens In.. OX40 is a member of the TNF superfamily, and is now at the forefront of the field known as “T..

A213-3D-TGA-thumb

Read More Poster 3D-Tumor Growth Assay Data Correlate with In Vivo Efficacy Study Results Current preclinical in vitro and in vivo models lack human stromal cells, and are therefore not..

B002-CD47-thumb-1

Read More Poster Developing Novel Immuno-Oncology Assays for Anti-CD47 Research Expressing CD47 is a technique used by most human tumors to escape macrophage surveillance...

B008-Gut-Microbiota

Read More Poster Gut Microbiota Abundance Regulated by Anti-PD-1 Treatment New research has revealed that gut microbiota has the potential to act as biomarkers that could..

Read More Poster Cost Effective, In Vivo Syngeneic I/O Agent Screening Panel In vitro cell-based screens frequently used in oncology to quickly identify responsive cells,..

B078-MiXeno-Poster

Read More Poster PBMC Humanized In Vivo Models for Evaluation of Human-Specific I/O Agents There are multiple published strategies for creating humanized mouse models, including..

Read More Poster PDX as Surrogate Models for TME Investigation It is being increasingly recognized that cancers are collections of diverse immune, as well as..

AACR-TII-2017-A05-Microbiota-Poster-THUMB

Read More Poster Anti-PD-1 Treatment Induces Gut Microbiota Profile Changes Commensal microbiota plays an important role in both physiological and pathological processes..

AACR-TII-2017-A49-Phagocytosis-Poster

Read More Poster A Novel Immunotherapy Approach Against Cancer Most human tumors express CD47 to escape macrophage surveillance. Therefore targeting CD47 to..

AACR-TII-2017-B28-MiXeno-Poster-THUMB

Read More Poster MiXeno™ – Simple, Fast, and Cost-Effective Humanized Models Preclinical humanized mouse models are required to assess human-specific therapeutics. Different..

cimt-poster-thumb

Read More Poster Humanized CD137 Models for Preclinical Drug Development PD-1/PD-L1 checkpoint inhibitors have achieved huge clinical success (and drug approval) across..

Read More Poster Evaluate Human Specific CD137 Antibodies Despite the huge clinical success of PD-1/PD-L1 checkpoint inhibitors in multiple tumor types,..

Read More Poster WES - A Better Approach to PDX CNV Detection Prediction of DNA copy number variation (CNV) is a critical component of genomic profiling, as..

Read More Poster MiXeno™ - a Rapid and Simple Strategy for Model Humanization Despite the unprecedented success of immune checkpoint antibodies for a variety of cancer types,..

Read More Poster CD137 Target Humanized Model Established CD137 belongs to the TNF receptor super family, and its activation is essential to the function..

Read More Poster MuScreen™ – the First In Vivo IO Syngeneic Screening Platform Immunotherapeutics can be difficult to evaluate preclinically - in vitro cell-based screens..

Read More Poster Exploring Immunotherapies Through BLI Subcutaneous syngeneic models are widely used to evaluate the impact of immunotherapy on tumor..

Read More Poster Microbiota Dynamically Facilitate Anti-PD-L1 Efficacy Cancer immunotherapies such as antibodies targeting programmed death-ligand 1 (PD-L1), a..

Read More Poster Anti-PD-1 Induced Microbiota Changes Increasing evidence has shown that gut microbiota play an important role in shaping systemic..

Read More Poster MuPrime™ – A Novel Mouse Model for PARP Inhibitor Evaluation PARP inhibitors (PARPi) have seen a resurgence since their approval for BRCA mutated ovarian..

Read More Poster Evaluate TILs and TAMs in Syngeneic Models CrownBio has developed a syngeneic model screening platform to facilitate the preclinical..

Read More Poster Discover New PDX Models for Prostate Cancer Prostate cancer is the second most common cancer worldwide for males, and the fourth most common..

Read More Poster A Novel PDX Model to Evaluate FL-HCC Therapies Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare and distinct primary hepatic..

Read More Poster How to Design and Analyse your MCT Patient-derived xenografts (PDX) are a well-accepted experimental cancer model mimicking..

Read More Poster In Vitro Combination Screening of IO and Targeted Agents CrownBio has developed a syngeneic model screening platform to facilitate the preclinical..

poster-atmc-2016-muscreen-thumb

Read More Poster A Panel of Well-Characterized Syngeneic Models for MuScreen™ In Vivo Screening In vitro screening is frequently used in oncology to quickly identify responsive cells, models,..

poster-aacr-2016-747-thumb

Read More Poster Autocrine c-Met/HGF HCC PDX: Evaluation of a Biologic Targeting c-Met The mesenchymal-epithelial transition factor (c-Met) represents an important target for cancer..

poster-aacr-2016-3219-thumb

Read More Poster Immunization is Critical to PD-1/PD- L1 Response in a Mouse Breast Cancer.. Immuno-oncology is an area under intense investigation due to the successful development of..

poster-aacr-2016-3994-thumb

Read More Poster Immunology Syngeneic Models Demonstrate Additive Effects of Combination.. Recent progress in the field of cancer immunotherapy (IT) has made it possible to translate..

poster-aacr-2016-4043-thumb

Read More Poster A Novel Mouse Skin Squamous Cell Carcinoma Allograft Model for In Vivo.. The recent clinical success of novel therapeutics blocking the immune checkpoints cytotoxic..

poster-aacr-2016-5176-thumb

Read More Poster Orthotopic Syngeneic Tumor Models for Preclinical Evaluation of Cancer.. The recent clinical success of immunotherapy in indications such as melanoma and lung cancer has..

poster-aacr-2016-5177-thumb

Read More Poster RNAseq and FACS Profiling of Syngeneic Mouse Models Treated with Immune.. Syngeneic tumor models have long been used in cancer research. Recently, the clinical success..

poster-aacr-2016-5179-thumb

Read More Poster Development of a Humanized Mouse Model for Direct Evaluation of Anti-Human.. Therapies that perturb binding of the programmed death-ligand 1 (PD-L1) to its receptor,..

poster-aacr-2016-5186-thumb

Read More Poster Using HuTrial™ to Aid in Predicting a Patient Population of Responders One of the biggest challenges in drug discovery is directing drug treatment to the correct..

poster-aacr-2016-6444-thumb

Read More Poster MiXeno™ Humanized Mouse Model as an Efficient Tool to Evaluate In Vivo Activity.. Pancreatic ductal adenocarcinoma (PDA) remains one of the most aggressive tumors in humans. A..

poster-aacr-2015-765-thumb

Read More Poster Overcoming Acquired Resistance in NSCLC with Targeted Beam Irradiation in.. Lung cancer is the largest cancer killer with poor 5-year survival rate. Non-small cell lung..

poster-aacr-2015-769-thumb

Read More Poster In Vivo Response and Molecular Characterization of a Caucasian NSCLC Squamous.. The fbroblast growth factor receptor (FGFR) family are reported to be involved in key cellular..

poster-aacr-2015-1038-thumb

Read More Poster Cell-based Screening Identifies Gene Expression Signature Correlated with.. The PI3K-Akt-mTOR signaling cascade is one of the most well known pro-proliferation and..

poster-aacr-2015-1472-thumb

Read More Poster Building a Comprehensive and Fully Annotated Patient Tumor Derived Xenograft.. Patient derived xenografts (PDXs) mirror patients’ pathology and genetic profles, and are..

poster-aacr-2015-1802-thumb

Read More Poster Application of Small Animal Image-Guided Irradiation to Preclinical In Vivo.. Patient derived xenograft (PDX) models sustain tumour heterogeneity and genetic integrity of the..

poster-aacr-2015-1926-thumb

Read More Poster Patient-Derived Xenograft Seem to Have Closer Global Expression Profile to that.. Patient derived xenografts (PDXs) without in vitro manipulation are believed to mirror original..

poster-aacr-2015-2281-thumb

Read More Poster Building Mouse Tumor Derived Allografts for Immuno-Oncology Research Limited types/numbers of available syngenic cells also restrict its application. Genetically..

poster-aacr-2015-3221-thumb

Read More Poster A Patient-Derived Xenograft (PDX) Platform for Development of Next Generation.. Despite best efforts in the treatment of gastrointestinal stromal tumors (GIST), patients..

poster-aacr-2015-3224-thumb

Read More Poster Living Tumor Bank and Patient-Derived Xenograft Models: A Powerful.. Patient-derived xenograft (PDX) models have been established from the world’s largest living..

poster-aacr-2015-3226-thumb

Read More Poster Patient-Derived Xenograft (PDX) Models for Triple Negative Breast Cancer.. In the United States, TNBC comprises 15-20% of breast cancers and are characterized by the lack..

poster-aacr-2015-3235-thumb

Read More Poster Validation of Anti-Human PD-1 and PD-L1 Antibodies in MiXeno™ Mouse Models As evidenced by strong clinical data from antibodies targeting cytotoxic T-lymphocyte antigen 4..

poster-aacr-2015-3581-thumb

Read More Poster Rapid Conversion to Resistance of a Colon PDX with RET Fusion by Ponatinib.. RET encodes a receptor tyrosine kinase (RTK) involved in cellular mechanisms of proliferation,..

poster-aacr-2015-4209-thumb

Read More Poster Development of Patient-Derived Xenograft Models for Small Cell Lung Cancer as a.. Small cell lung cancer comprises 15-20% of all lung cancer cases, and is more invasive and has a..

poster-aacr-nci-eortc-2015-247-thumb

Read More Poster Drug Resistant Murine Tumor Models Facilitate the Development of Next.. Despite the development of promising new anticancer drugs, all cancer therapeutics, including..

poster-aacr-nci-eortc-2015-382-thumb

Read More Poster Response to Checkpoint Inhibition by GEMM Breast Cancer Allograft Response to immunotherapy (I/O, e.g. to checkpoint inhibitors) in cancer patients, differs..

poster-aacr-nci-eortc-2015-394-thumb

Read More Poster Induction of Resistances to Crizotinib in NSCLC Patient-Derived Xenograft.. Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase, and its mutation,..

poster-aacr-nci-eortc-2015-396-thumb

Read More Poster Molecular Pathology of Patient Tumors, Patient-Derived Xenografts and Cancer.. Cancers are heterogeneous diseases with diverse pathogenesis. Clinical diagnosis is primarily..

poster-aacr-nci-eortc-2015-399-thumb

Read More Poster A HuGEMM h/mPD1 Mouse Model for Testing Anti-Human PD-1 Therapeutics The recent approval of two monoclonal antibodies targeting the immune checkpoint programmed cell..

poster-ash-2015-2759-thumb

Read More Poster Activating Mutations in MYD88 and CD79B Are Predictive of Response to Ibrutinib.. DLBCL is the most common form of nonHodgkin’s lymphoma (NHL) consisting in 2 subtypes: the..

poster-cri-cimt-eati-aacr-2015-b115-thumb

Read More Poster Application of Image-Guided Irradiation to a Preclinical Bioluminescent.. Radiotherapy is a primary, adjuvant or neoadjuvant treatment for a number of different cancers..

poster-cri-cimt-eati-aacr-2015-b117-thumb

Read More Poster Profiling of Syngeneic Models by Check Point Inhibitors, RNAseq, and FACS.. Syngeneic tumor models have long been used in cancer research. The recent clinical success of..

poster-ecco-2015-228-thumb

Read More Poster Preclinical Mouse Trials (MCT) to Guide the Human Studies Patient-derived xenograft (PDX) tumor models are widely used for assessing cancer treatments,..

poster-ecco-2015-201-thumb

Read More Poster Profiling of Syngeneic Models by Anti-PD-1, PD-L1 and CTLA-4 Immunotherapeutics.. Syngeneic tumor models have long been used in cancer research. The recent clinical success of..

poster-nhcr-2015-87-thumb

Read More Poster A Novel RET TKI Inhibits Growth of Patient-Derived Xenografts with RET Fusion.. Activation of RET, a RTK proto-oncogene, is associated with the development of several human..

poster-nhcr-2015-36-thumb

Read More Poster Drug Resistant Murine Tumor Models Facilitate Development of Next Generation.. Despite the development of promising new anticancer drugs, all cancer therapeutics, including..

poster-nhcr-2015-103-thumb

Read More Poster Establishment of a Humanized PD-1 Mouse Model for In Vivo Pharmacological.. The recent approval of two immunotherapeutic agents targeting the immune checkpoint programmed..

poster-nhcr-2015-95-thumb

Read More Poster Establishment of a Mouse Breast Cancer Allograft Model for In Vivo.. The recent clinical success of novel therapeutics blocking the immune checkpoints cytotoxic..

poster-nhcr-2015-90-thumb

Read More Poster High Efficacy of a Novel and Specific c-MET TKI in a Cohort of PDXs from.. Turning on c-Met signaling, through gene amplification, activating mutations or interaction with..

poster-2015-121-thumb

Read More Poster Immunological Characterization: Allograft of Primary Murine Breast Cancer.. Thanks to the recent success in clinical trials, immunotherapy has become the main focus of..

thumb-aacr-1206

Read More Poster Parameters Influencing Design of Mouse Clinical Trial (HuTrial™) Patient-derived xenograft (PDX) is increasingly used to evaluate oncology drug. The fast..

thumb-aacr-2054-1

Read More Poster Patient Relevant Preclinical In Vivo Models Using Image-Guided Small Animal.. We have recently successfully engrafted leukemic cells from bone marrow of 4 AML patients into..

thumb-aacr-2562

Read More Poster Evaluate In Vivo Efficacy of Antitumor Immunotherapeutics Using MiXeno™ Mouse.. The past few years have witnessed a renaissance in the field of cancer immunotherapy, relating..

thumb-aacr-3123

Read More Poster Modeling Anti-Leukemic Therapy by Patient-Derived AML Xenografts with Distinct.. We have recently successfully engrafted leukemic cells, isolated from bone marrows of 3 AML..

thumb-aacr-3124-3

Read More Poster Xenograft Models for Development of New Drugs Targeting Fibroblast Growth.. The fibroblast growth factor receptors (FGFR) are tyrosine kinases that are present in many..

thumb-aacr-3136

Read More Poster X-MAN™ Isogenic DualXeno™ Models with KRAS Mutation Predicts the Effect of.. We have previously reported using cell lines generated with Horizon Discovery’s rAAV-based..

thumb-aacr-3440

Read More Poster Cell-based Screening Identifies Gene Expression Signature Correlated with.. The Ras-Raf-MEK-ERK signaling cascade is one of the most well known pro-proliferation and..

thumb-aacr-4875

Read More Poster In Vivo and In Vitro Generation and Characterisation of EGFR-TKI Resistance in.. Most non-small cell lung cancer (NSCLC) patients that have activating mutations in the EGFR gene..

thumb-syngeneic-models

Read More Poster Syngeneic Models for Developing Cancer Therapeutics Targeting Immune System Syngeneic tumor models have long been used in cancer research, from mechanistic study to..

thumb-patient-derived-nsclc-xenograft

Read More Poster Treatment of Patient-Derived NSCLC Xenograft Preclinical Models Using.. Radiotherapy is a primary, adjuvant or neoadjuvant treatment for a number of different cancers..

thumb-poster-nsclc

Read More Poster Development of a Gene Signature for Stratifying Cisplatin Treatment of NSCLC.. Cancer is not a single disease, reflecting that no single treatment can be broadly effective to..

thumb-poster-xenograft

Read More Poster Induction of Resistance to Targeted Therapies in Patient-Derived Xenograft.. Oncogene activating mutations have been found to be oncogenic drivers in many different cancers,..

thumb-poster-aml

Read More Poster Patient-Derived AML Xenografts for Drug Evaluation We have recently successfully engrafted leukemic cells from bone marrow of 4 AML patients into..

thumb-pub-ccrcc-intra-tumor

Read More Publication ccRCC Intra-Tumor Molecular Heterogeneity Influences Targeted Therapy Response Both inter- and intra-tumor molecular heterogeneity are increasingly being recognized in clear..

thumb-pub-optimizing-inhimbitors

Read More Publication Optimizing Inhibitors for RET Rearranged Tumors The targeted inhibition of oncogenic driver mutations is an underlying principle of oncology..

thumb-pub-intro-to-preclincial-immuno

Read More Publication Introduction to Preclinical Immuno-Oncology In Vivo Models Immuno-oncology research has dramatically increased over the past few years, due to the clinical..

thumb-crc-sensitivity

Read More Publication CRC Sensitivity to Proteasome Inhibitor Investigated Colorectal cancer (CRC) has a low 5 year survival rate, due to the late diagnosis of advanced..

thumb-pub-first-in-class-pikfyve

Read More Publication First-in-Class PIKfyve Kinase Inhibitor for B-NHL Identified Non-Hodgkin lymphoma (NHL) covers a group of lymphoproliferative malignancies with subtypes..

thumb-pub-first-stable-serially

Read More Publication First Stable, Serially Transplantable M5 AML PDX Model Patient-derived xenografts (PDX) have proven to be useful preclinical research tools across many..

thumb-expression-based-ras

Read More Publication Expression Based RAS Pathway Predicts CRC Cetuximab Response Cetuximab is approved for the treatment of metastatic colorectal cancer (mCRC), excluding..

thumb-pub-confirmed-high-relevance

Read More Publication Confirmed - High Relevance of PDX as Surrogate Experimental Models The accurate diagnosis of cancer types is needed to understand disease development and..

thumb-pub-nsclc-pdx-models

Read More Publication NSCLC PDX Models with EGFR Exon 20 Insertions Developed Activating EGFR mutations are oncogenic drivers in a significant proportion of NSCLC cases...

thumb-pub-novel-ex-vivo-3d-tumor

Read More Publication Novel Ex Vivo 3D Tumor Growth Assay for PDX Developed It is increasingly recognized that preclinical models do not fully reflect the tumor..

thumb-pub-design-and-optimization

Read More Publication Design and Optimization of DAAP ALK Inhibitors Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase belonging to the insulin receptor..

thumb-pub-oncogenic-allele

Read More Publication Oncogenic Allele Signature Predicts CRC Cetuximab Response Cetuximab is an approved standard of care agent for EGFR+ metastatic colorectal cancer (mCRC),..

thumb-pub-new-daap-alk-1

Read More Publication New DAAP ALK Inhibitor Series Discovered Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that belongs to the insulin..

thumb-pub-metastatic-gastric-neuroendocrine-3

Read More Publication Metastatic Gastric Neuroendocrine Carcinoma PDX Model Developed Patient-derived xenograft (PDX) models show improved predictability for drug development..

thumb-pub-cancer-stem-cells-targeted-1

Read More Publication Cancer Stem Cells Targeted by PI3K/mTOR Inhibitor Cancer stem cells (CSC) are implicated in chemoresistance, as well as disease metastasis,..

thumb-pub-predicting-cetuximab-1

Read More Publication Predicting Cetuximab Response in Gastric Cancer using MCT Gastric cancer (GC), specifically gastric adenocarcinoma, is one of the leading causes of cancer..

thumb-pub-novel-multitarget-kinase-1

Read More Publication Novel Multitarget Kinase Inhibitor for HCC and GC Discovered Protein kinases are successful therapeutic targets in oncology, validated by the broad..

thumb-pub-vegi-potential-tumor

Read More Publication VEGI is a Potential Tumor Suppressor in RCC While vascular endothelial growth inhibitor (VEGI) has been associated with tumor-related..

thumb-pub-overcome-efgr-tki

Read More Publication How to Overcome EGFR TKI Resistance in NSCLC EGFR tyrosine kinase inhibitors (TKI) including erlotinib have provided significant clinical..

thumb-pub-optimization-of-hdac

Read More Publication Optimization of HDAC Inhibitors for HCC Hepatocellular carcinoma (HCC) is among the leading causes of cancer death worldwide, with poor..

Read More FactSheet CAR-T Therapy Preclinical evaluation of CAR-T therapies in vivo using our novel Patient-Derived Xenograft..

thumb-fs-mixeno

Read More FactSheet MiXeno™ MiXeno™ models featuring transient human immunity in mice, providing a simple alternative to the..

thumb-fs-hugemm-hucell

Read More FactSheet HuGEMM™ and HuCELL™ Models HuGEMM™ and HuCELL™, our unique platforms for evaluation of targeted human-specific..

thumb-fs-syngeneic

Read More FactSheet Syngeneic Models Syngeneic models, showcasing our ever expanding syngeneic collection, FACS analysis, and..

thumb-fs-muscreen

Read More FactSheet MuScreen™ MuScreen™ CrownBio’s large-scale, screening platform to fast-track the in vivo screening of..

thumb-fs-muprime

Read More FactSheet MuPrime™ Model MuPrime™ - homografts of spontaneous murine tumors (from GEMM/carcinogen-induced models),..

Read More FactSheet RET Fusion RET fusion in CRC PDX models, including model response to RET inhibitor treatment, and the..

Read More FactSheet FGFR3 Fusion In Vivo Xenograft Platform Our FGFR3 fusion in vivo xenograft platform covering both patient and cell line derived..

Read More FactSheet HuPrime® Our PDX collection key features are summarized in our HuPrime® FactSheet

thumb-fs-hukemia

Read More FactSheet HuKemia® Discover our validated stable HuKemia® models, the only commercial blood cancer PDX models to..

Read More FactSheet GIST PDX Models Use the world's most comprehensive GIST PDX collection to evaluate the next generation of..

Read More FactSheet NHL DLBCL PDX Models Read how to accelerate NHL DLBCL targeted agent and combination therapy drug discovery programs..

thumb-odw-microbiome

Watch Now On-Demand Webinar Microbiome Drug Development with Whole Communities and Defined Consortia Microbiome therapies are still in their infancy, but are rapidly advancing into clinical testing..

thumb-odw-right-model

Watch Now On-Demand Webinar Are You Choosing the Right Model? A Guide to Selecting Your Next.. Recent regulatory approvals and fast-track designations have signified the coming of age of..

thumb-odw-beyond-syngeneics

Watch Now On-Demand Webinar Beyond Syngeneics – Novel Tools for Addressing Human Specificity in.. Checkpoint inhibitors such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 have revolutionized..

thumb-odw-clinically-relevant

Watch Now On-Demand Webinar Clinically Relevant Cell-Based Solutions for Target Identification Target identification studies play a critical role in the early stages of cancer drug discovery..

thumb-fs-3d-cell

Read More FactSheet 3D Cell Culture Platform In Vitro/Ex Vivo Assays for Cancer Pharmacology Our 3D cell culture platforms described in detail, including the 3D tumor growth assay (3D TGA)..

thumb-odw-exploring-translational

Watch Now On-Demand Webinar Exploring Translational Capabilities of PDX Models across In Vivo, In Vitro and.. The development of novel cancer therapies to take into the clinic requires significant..

thumb-odw-immuno-oncology

Watch Now On-Demand Webinar Immuno-Oncology: 3 Strategies for Applying Humanized Models The evaluation of human specific immunotherapeutics is hampered by a lack of preclinical..

thumb-odw-exvivo-invitro

Watch Now On-Demand Webinar In Vitro and Ex Vivo Assays to Accelerate Immuno-Oncology Drug Discovery Immunotherapy represents one of the most promising cancer treatment approaches in modern..

thumb-odw-syngeneic-models

Watch Now On-Demand Webinar Interrogating Syngeneic Models in Large Scale, How to Use Immunoprofiling Data.. Syngeneic models are a standard preclinical platform for evaluating immunotherapies. However,..

Watch Now On-Demand Webinar Mouse Clinical Trials: The Power Behind Study Design It is widely known that the attrition rate of oncology drugs in the clinical setting can be..

thumb-odw-murine

Watch Now On-Demand Webinar Murine Immuno-Oncology Models: A Head-to-Head Comparison Between Syngeneics and.. Syngeneics have been the mainstay model for surrogate immunotherapy evaluation as an..

thumb-odw-xenografts

Watch Now On-Demand Webinar Patient-Derived Xenografts: New Advancements in Preclinical Prostate Cancer.. Prostate cancer is a highly heterogeneous disease, with extremely complex biological, hormonal,..

thumb-odw-mouse-clinical-trials

Watch Now On-Demand Webinar The Ultimate Guide to Mouse Clinical Trials The cost of bringing a new drug to market carries a high price, however it is even more costly..

thumb-app-note-hutrial

Read More Application Note HuTrial™ Case Studies CrownBio presents a variety of interesting and diverse mouse clinical trials, using our PDX..

thumb-invitro-exvivo

Read More Application Note In Vitro and Ex Vivo Immuno-Oncology Drug Discovery Discover how CrownBio’s comprehensive Immuno-Oncology platform allows end-to-end in vitro and ex..

thumb-qf-inflammation-ibd-models

Read More Quick Fact IBD Models Preclinical platform to advance inflammation drug discovery

thumb-qf-inflammation-ra-models

Read More Quick Fact RA Models Translational preclinical platform to speed RA drug discovery

Read More Quick Fact 3D PDX Screen A rapid translational ex vivo screening platform

Read More Quick Fact CrownSyn™ Bioinformatics tool to simplify two-drug combination analysis

Read More Quick Fact HuBase™ Online searchable Patient-Derived Xenograft (PDX) database

Read More Quick Fact HuKemia® Patient-derived blood cancer models

Read More Quick Fact HuMark™ Discovery and validation of novel oncology biomarkers

Read More Quick Fact HuPrime® The world’s largest commercial collection of well-characterized PDX models

thumb-husignature

Read More Quick Fact HuSignature™ Discovery and validation of genetic signatures of response

Read More Quick Fact HuTrial™ Mouse clinical trials using PDX models

thumb-immuno-oncology

Read More Quick Fact Immuno-Oncology Platforms Discover an integrated in vitro, ex vivo, and in vivo I/O model portfolio

thumb-omnipanel

Read More Quick Fact OmniPanel™ CrownBio collection of over 400 cell lines for in vitro studies

thumb-qf-omniscreen

Read More Quick Fact OmniScreen™ Well-validated, large-scale cell panel screening platform

thumb-oncoexpress

Read More Quick Fact OncoExpress™ One stop search engine for Oncology models including PDX, cell line derived xenografts, and..

thumb-primepanel

Read More Quick Fact PrimePanel™ PrimePanel are isolated primary cells from patient-derived tumor tissues for in vitro drug..

thumb-radiation-therapy

Read More Quick Fact Radiation Therapy Precision radiotherapy with applications from subcutaneous to metastatic studies

thumb-target-identification

Read More Quick Fact Cell-Based Target Identification Discover an integrated oncology portfolio providing cell-based solutions for target..

thumb-xeno-base

Read More Quick Fact XenoBase® - Which cell line is best for your cancer study? One click in XenoBase gives you instant access to a unique database of over 1000 tumor cell..

thumb-xeno-select

Read More Quick Fact XenoSelect™ - Faster in vitro to in vivo study translation A diverse, oncogenic in vitro screening panel of more than 150 cell lines ready for in vivo..

thumb-wp-translational

Read More White Paper Exploring Translational Capabilities of PDX Models across In Vivo, In Vitro,.. Patient-derived xenografts are recognized as the most predictive preclinical model available for..

thumb-wp-immuno-oncology

Read More White Paper How to Choose the Correct I/O Model As immuno-oncology continues to grow as a therapeutic area, more preclinical research is driven..

thumb-wp-portfolio

Read More White Paper Optimize Target Identification and MOA Studies Correctly identifying drug targets and elucidating MOA is a critical stage in early drug..

thumb-wp-3-strategies

Read More White Paper 3 Strategies for Applying Humanized Models Immunotherapeutics have proven to be a game changer in oncology – bringing tremendous patient..

thumb-wp-precision-profiling

Read More White Paper Precision Profiling With PDX Oncology drug development is inefficient and expensive, costs quickly spiral upwards while..

thumb-wp-clincial-trials

Read More White Paper The Ultimate Guide to Mouse Clinical Trials Traditional oncology drug development strategies are failing – oncology agents have a higher..

resources-wp-isotype-control-thumb

Read More White Paper The Importance of Using an Isotype Control The accurate measurement of drug effects requires the use of an appropriate negative control...